Since the in vivo anti-tumor efficacy of Akt inhibitor GSK690693 has been shown in mice bearing breast tumor, lymphoma, endometrial tumor, ovarian carcinoma, and osteosarcoma59, 60, we also examined the role of GSK690693 in the treatment of HE in animals. This evidence concerns the gene AKT1 and lymphoma.